A Statistical Study of Corona Virus in the City of Tarhuna from 2020 to 2022 and Their Impact on Patients with Chronic Diseases
DOI:
https://doi.org/10.61952/jlabw.v1i4.304Keywords:
Corona viruses, Epidemiological Study, , Chronic Disease and InfectionAbstract
Background: The study aimed to evaluate the risk factors and prevalence of Coronavirus infection among residents and expatriates in Tarhuna, highlighting the importance of virus detection and preventive measures like vaccination and antiviral therapies.
Materials and methods: From mid-February through late April 2025, researchers examined 718 coronavirus cases reported in Tarhona, Libya. They used information provided by the local pandemic task force to understand how frequently – moreover, where – the virus appeared across different people, regardless of their nationality.
Results: A look at 718 people revealed that roughly 12% more men than women tested positive for Coronavirus. Also within the group, nearly 3% lived with diabetes - a condition often linked to health problems. Among those with syndromes, 2.2% also had issues involving blood pressure or blood sugar - specifically, 16 were found to have high blood pressure. Smaller portions of individuals presented with conditions like diabetes (0.8%), kidney failure (0.7%), asthma (0.3%), underactive thyroid (0.3%) or Parkinson’s disease (0.3%).
Conclusion: The study concludes that there is a statistically significant difference in infection rates based on gender, with males being more frequently infected. It identifies that 2.9% of participants had diabetes, consistent with global trends regarding chronic illnesses. Additionally, 16.2% of individuals with both diabetes and hypertension faced health issues related to these conditions.
Recommendations: Highlight the importance of awareness campaigns aimed at men's health and the necessity of continuous education for individuals with chronic illnesses regarding health maintenance and infection prevention.
References
Fehr AR, Perlman S. COVID-19: An overview of their replication and pathogenesis. J Clin Virol. 2024;157:105298.
Maetouq HM, Mahmoud AS, El Salem A, et al. Preliminary epidemiological investigation of SARS-CoV-2 and risk factors associated with infection in Tarhouna, Libya. Fortune J Health Sci. 2024;7(1):45-53.
Centers for Disease Control and Prevention. CDC COVID Data Tracker [Internet]. Atlanta (GA): CDC; 2024 [cited 2024 Jun 26]. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-proportions
Mahdie B, Khatooni M, Senmar M, et al. The predictive role of social isolation in CORONAVIRUS anxiety among older adults. BMC Geriatr. 2025;25:375. doi:10.1186/s12877-025-06046-w.
Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. *Science.* 2020;369(6500):208–211. doi:10.1126/science.abc3517.
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi.* 2020;41(2):145–151. doi:10.3760/cma.j.issn.0254-6450.2020.02.003.
Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. *Ageing Res Rev.* 2021;65:101205. doi:10.1016/j.arr.2020.101205.
Elkarow MH, Hamdy A. A suggested role of human growth hormone in control of the COVID- 19 pandemic. *Front Endocrinol.* 2020;11:569633. doi:10.3389/fendo.2020.569633.
Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. *Pediatr Endocrinol Rev.* 2004;1(Suppl 3):490–495.
Elkarow MH, Hamdy A. A suggested role of human growth hormone in control of the COVID-19 pandemic. *Front Endocrinol.* 2020;11:569633. doi:10.3389/fendo.2020.569633.
Lubrano C, Masi D, Risi R, Balena A, Watanabe M, Mariani S, et al. Is growth hormone insufficiency the missing link between obesity, male gender, age, and COVID-19 severity? *Obesity (Silver Spring).* 2020;28(11):2038–2039. doi:10.1002/oby.23000.
Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. *PLoS Pathog.* 2020;16(6):e1008570. doi:10.1371/journal.ppat.1008570.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA.* 2020;323(18):1775–1776. doi:10.1001/jama.2020.4683.
Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA.* 2020;323(15):1488–1494. doi:10.1001/jama.2020.3204.
Khan MA. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: a systematic review and meta-analysis. *J Infect Public Health.* 2020;10(2):1–14.
Chenchula S, Vidyasagar K, Pathan S, et al. Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression. *Sci Rep.* 2023;13:33314. doi:10.1038/s41598-023-33314-9.
EpiCentro. Coronavirus – news [Internet]. Rome: Istituto Superiore di Sanità; 2022 [cited 2022 Dec 7]. Available from: https://www.epicentro.iss.it/coronavirus/aggiornamenti.
EpiCentro. Characteristics of COVID-19 patients dying in Italy [Internet]. Rome: Istituto Superiore di Sanità; 2022. Available from: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths.
Geng J, Yu X, Bao H, Feng Z, Yuan X, Zhang J, et al. Chronic diseases as a predictor for severity and mortality of COVID-19: a systematic review with cumulative meta-analysis. *Front Med (Lausanne).* 2021;8:588013. doi:10.3389/fmed.2021.588013.
Huluka DK, Etissa EK, Ahmed S, et al. Clinical characteristics and treatment outcomes of COVID-19 patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. *Am J Trop Med Hyg.* 2022;107(2):252. doi:10.4269/ajtmh.21-1270.
Albanghali M, Alghamdi S, Alzahrani M, et al. Clinical characteristics and treatment outcomes of mild to moderate COVID-19 patients at tertiary care hospital, Al Baha, Saudi Arabia: a single centre study. *J Infect Public Health.* 2022;15(3):331–337. doi:10.1016/j.jiph.2022.02.001.
Yates T, Zaccardi F, Islam N, Razieh C, Gillies CL, Lawson CA, et al. Obesity, chronic disease, age, and in-hospital mortality in patients with COVID-19: analysis of ISARIC clinical characterisation protocol UK cohort. *BMC Infect Dis.* 2021;21(1):717. doi:10.1186/s12879-021-06466-0.
Htun NSN, Odermatt P, Eze IC, Boillat-Blanco N, D'Acremont V, Probst-Hensch N. Is diabetes a risk factor for a severe clinical presentation of dengue?—Review and meta-analysis. *PLoS Negl Trop Dis.* 2015;9(4):e0003741.
Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. *Curr Hypertens Rep.* 2010;12(6):448–455.
Magen E, Feldman A, Cohen Z, Alon DB, Linov L, Mishal J, et al. Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension. *Am J Med Sci.* 2010;339(5):415–419.
Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. *Hypertension.* 2009;54(3):619–624.
Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the Greater Toronto Area. *JAMA.* 2003;289(21):2801–2809.
Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. *Diabet Med.* 2006;23(6):623–628.
Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. *Diabetes Care.* 2010;33(7):1491–1493.
van den Brand JM, Smits SL, Haagmans BL. Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 2015;235:175–184.
Wu J, Li W, Shi X. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020.
Yang J, Zheng Y, Gou X. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020.
Emami A, Javanmardi F, Pirbonyeh N. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8:e35.
Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020.
Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.
Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Zaher K, Basingab F, Alrahimi J, Basahel K, Aldahlawi A. Gender differences in response to COVID-19 infection and vaccination. Biomedicines. 2023;11(6):1677. doi:10.3390/biomedicines11061677.
Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi:10.1371/journal.pone.0240784.
Rosenbaum PR. A characterization of optimal designs for observational studies. J R Stat Soc B. 1991;53(3):597–610. doi:10.1111/j.2517-6161.1991.tb01848.x.
van Buuren S, Groothuis-Oudshoorn K. MICE: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
Pishgar F, Greifer N, Leyrat C, Stuart E. MatchThem: matching and weighting after multiple imputation. R J. 2021;13(2):292–305.
Lim SH, Ju HJ, Han JH, et al. Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open. 2023;6(10):e2336120. doi:10.1001/jamanetworkopen.2023.36120.
Tleyjeh IM, Saddik B, AlSwaidan N, et al. Prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLoS One. 2021;16(12):e0260568. doi:10.1371/journal.pone.0260568.
Boden M, Cohen N, Froelich JM, Hoggatt KJ, Abdel Magid HS, Mushiana SS. Mental disorder prevalence among populations impacted by coronavirus pandemics: a multilevel meta-analytic study of COVID-19, MERS and SARS. Gen Hosp Psychiatry. 2021;70:124–133. doi:10.1016/j.genhosppsych.2021.03.006.
Peters BA, Xue X, Sheira LA, et al. Menopause is associated with immune activation in women with HIV. J Infect Dis. 2022;225(2):295–305. doi:10.1093/infdis/jiab341.
Cinislioglu AE, Cinislioglu N, Demirdogen SO, et al. The relationship of serum testosterone levels with the clinical course and prognosis of COVID-19 disease in male patients: a prospective study. Andrology. 2022;10(1):24–33. doi:10.1111/andr.13081.
Salonia A, Pontillo M, Capogrosso P, et al. Severely low testosterone in males with COVID-19: a case-control study. Andrology. 2021;9(4):1043–1052. doi:10.1111/andr.12993.
Klein SL. Sex and gender differences in pharmacology. In: Sex Differences in Prophylaxis and Therapeutic Treatments for Viral Diseases. 2013:499–522.
Gubbels Bupp MR, Potluri T, Fink AL, Klein SL. The confluence of sex hormones and aging on immunity. Front Immunol. 2018;9:1269. doi:10.3389/fimmu.2018.01269.
Al-Lami RA, Urban RJ, Volpi E, Algburi AM, Baillargeon J. Sex hormones and novel coronavirus infectious disease (COVID-19). Mayo Clin Proc. 2020;95:1710–1714. doi:10.1016/j.mayocp.2020.05.013.
Seeland U, Coluzzi F, Simmaco M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18:369. doi:10.1186/s12916-020-01851-z.
Vega-Alonso T, Lozano-Alonso JE, Ordax-Díez A; VIGIRA Research Group. Comprehensive surveillance of acute respiratory infections during the COVID-19 pandemic: a methodological approach using sentinel networks, Castilla y León, Spain, January 2020 to May 2022. Euro Surveill. 2023;28(21):2200638. doi:10.2807/1560-7917.ES.2023.28.21.2200638.
Cai W, Dürrwald R, Biere B, Schweiger B, Haas W, Wolff T, et al. Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany. Influenza Other Respir Viruses. 2022;16(5):854–857. doi:10.1111/irv.12996.
Graham MS, Sudre CH, May A. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021;6:e335–e345.
Del Rio C, Malani PN, Omer SB. Confronting the Delta variant of SARS-CoV-2, summer 2021. JAMA. 2021;326:1001–1002.
Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. Science. 2021;372:1375–1376.
Wang Y, Chen R, Hu F. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021;40:101129.
Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–4236.e13.
Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398:2126–2128.
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603:700–705.
Rao S, Singh M. The newly detected B.1.1.529 (Omicron) variant of SARS-CoV-2 with multiple mutations: implications for transmission, diagnostics, therapeutics, and immune evasion. DHR Proc. 2021;1:7–10.
Meng B, Abdullahi A, Ferreira TMI, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714.
Bálint G, Vörös-Horváth B, Széchenyi A. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther. 2022;7:151.
Ulloa AC, Buchan SA, Daneman N. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. JAMA. 2022;327:1286–1288.
